ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

... and set up Czech center

July 24, 2006 | APPEARED IN VOLUME 84, ISSUE 30

Gilead plans to provide $1.1 million annually for five years to the Institute of Organic Chemistry & Biochemistry at the Academy of Sciences of the Czech Republic (IOCB) to help establish a research facility. Gilead has licensing agreements with IOCB and the Rega Institute for Medical Research at Belgium's Katholic University dating back to 1991 for a range of nucleotide analog compounds and structures. Several of them have been developed by Gilead, resulting in the HIV treatment Viread and other drugs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment